Publication | Open Access

Impact of angiotensin I converting enzyme inhibitors and angiotensin II type 1 receptor blockers on survival in patients with advanced non-small-cell lung cancer undergoing first-line platinum-based chemotherapy

MedicinePharmacologyBronchial NeoplasmImmune Checkpoint InhibitorPharmacotherapyCancer TreatmentReceptor BlockersEnzyme InhibitorsOncologyLung CancerFirst-line Platinum-based Chemotherapy